Short-time Clinical Therapeutic Effects Of Intravitreal Rani Bizumab Injection For Macular Edema

Objective To evaluate the short time clinical therapeutic efficacy and safety of intravitreal Ranibizumab injection for macular edemaMethods Forty-two eyes with macular edema.the baseline examination include i ntraocular pressure(IOP),fundus fluorescein angiography(FFA)and thickness of the neurosensory retina and the central volume of macular measured with optical coh erence tomography(OCT)at one day、one month、three months and six months f ollow-up.Results The BCVA of baseline was38.8±20.47letters,and the BCVA at one da y、one month、three months and six months follow-up were46.9±16.83letters、55.3±17.191etters、57.5±18.19letters、54.8±17.8letters,and were significantly bette r than that at baseline(P=0.000,P=0.002,P=0.008,P=0.005),all the differences have statistical significances.the one month follow-up BCVA had significant difference with that at after one day(P=0.001).the three months follow-up BCVA had signifi cant difference with that at after one month (P=0.000), the six months follow-up BCVA had significant difference with that at after three months (P=0.000).Afte r six months follow-up,the BCVA had significant difference compared to that at t he baseline(P=0.003). the central retinal thickness(CRT) of baseline was660.29±336.5μm,the c entral retinal thickness(CRT) at one day、one month、three months and six mon ths follow-up after injection were575.52±311.9μm、452.1±239.3μm、417.95±194.9μm、422.29±197.0μm,ane were reduced significantly compared to the baseline((P=0.000,P=0.000,P=0.000,P=0.000),all the differences have statistical significances.it at one month follow-up significantly reduced compared that at one day(P=0.001). At the three months,the central macular thickness had significant difference comp ared to that at after one month(P=0.000),at the six months, the central macular t hickness had significant difference compared to that at after three months(P=0.003).At six months follow-up,the central macular thickness reduced significantly compared to the baseline(P=0.000)the central macular volume(CMV) within1m m of baseline was0.3135±0.183mm3,the central macular volume(CMV) within1mm at one day、one month、three months and six months-up after injection w ere0.2689±0.152mm3、0.2397±0.113mm3、0.2181±0.095mm3、0.2078±0.096mm3,an d were reduced significantly compared to the baseline((P=0.000,P=0.000,P=0.002,P=0.001),all the differences have statistical significances.the two months follow-up the central macular volume(CMV) within lmm had significant difference with t hat at after one month (P=0.000), the three months follow-up BCVA had signifi cant difference with that at after two months (P=0.004).After six months follow-up,the the central macular volume(CMV) within lmm had significant difference compared to that at the baseline(P=0.002).At the six months follow-up,the mean IOP was normal.All patients had no complications such as inflammation,infectious endophthalmitis,vitreous hemorrhage and retinal detachment. ConclusionWith the method of the measurement of the central macular volume(CMV),T he Intravitreal Ranibizumab injection is a relatively safe and effective treatment method for the short-term control of macular edema with less complications visu alized, and also could be better illustrate the outcome of the disease with the me thod of measuring of CMV.